Aon Invests in eMed to Scale GLP-1 Population Health Platform, Enhancing Obesity Solutions and Health Outcomes for Employers

Aon, a global professional services firm, has made a strategic investment in eMed Population Health to scale its GLP-1 population health platform. The partnership aims to enhance employer-sponsored access to GLP-1 therapies and deliver breakthrough health outcomes with cost savings. Aon's subsidized GLP-1 weight management benefit program for its US workforce has seen strong adherence, high retention, and sustainable results. eMed will increase distribution of its digital-first healthcare platform to reach more employers and patients.

Aon plc, a leading global professional services firm, has announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership aims to enhance employer-sponsored access to GLP-1 therapies and deliver breakthrough health outcomes with cost savings. This investment follows the successful launch of Aon's subsidized GLP-1 weight management benefit program for its U.S. workforce, which has demonstrated strong adherence, high retention, and sustainable results. In the six months since the program's launch, more than 1,200 people have registered, with an average weight loss of 22.4 pounds and a retention rate of 95% [1].

The investment will enable eMed to continue scaling its digital-first healthcare platform, which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support. This platform will reach more employers and patients, expanding the accessibility of GLP-1 therapies. "This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people," said Lisa Stevens, Chief Administrative Officer for Aon [1].

eMed's platform, built on Empathetic AI™, empowers employers to manage population health with accountability and compassion. The collaboration marks a significant milestone in eMed's mission to deliver effective and sustainable care through an integrated, data-driven experience. "Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants," said Linda Yaccarino, CEO of eMed Population Health, Inc. [1].

Aon continues to build a complementary suite of GLP-1 solutions, industry-leading experience, and advisory capabilities for clients. The obesity treatment landscape is undergoing a seismic shift, with GLP-1 receptor agonists (GLP-1RAs) like Ozempic, Wegovy, and Mounjaro dominating headlines for their ability to drive rapid weight loss. However, a critical flaw remains unaddressed: sustainability. Patients often regain lost weight within months of discontinuing these injectable therapies, creating a $12.7 billion obesity drug market gap for solutions that enable long-term maintenance [2].

Aardvark Therapeutics is addressing this gap with its investigational oral therapy ARD-201, a dual-action candidate designed to tackle post-GLP-1RA weight maintenance. ARD-201 combines TAS2R activation and DPP-4 inhibition, offering a novel oral approach to obesity management. Preclinical data shows ARD-201 prevents weight rebound in mice post-tirzepatide discontinuation and enhances efficacy when combined with low-dose GLP-1RAs. Phase 2 trials will test weight maintenance and lean mass preservation, positioning ARD-201 as a potential $20-30 billion market solution for post-GLP-1RA obesity management [2].

References:
[1] https://www.marketscreener.com/news/aon-announces-strategic-investment-in-emed-to-scale-glp-1-population-health-platform-ce7c51dcd981f621
[2] https://www.ainvest.com/news/aardvark-therapeutics-obesity-market-gap-ard-201-redefine-long-term-weight-management-2508/